Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Return on Capital Employed (ROCE) for the year ending December 31, 2023: -53.23%

Crossject SA Return on Capital Employed (ROCE) is -53.23% for the year ending December 31, 2023, a 7.61% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Crossject SA Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -57.61%, a -22.37% change year over year.
Crossject SA Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -47.08%, a -4.05% change year over year.
Crossject SA Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -45.24%, a -3.76% change year over year.
Crossject SA Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -43.60%, a 38.50% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years